ArticleDiscover oncology2025
Disulfidptosis-related LncRNA signatures in gastric cancer: regulation of MYH10-driven cytoskeletal remodeling and therapeutic implications.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Disulfidptosis as an immunometabolic rheostat in gastrointestinal cancers: tuning the balance between T Cell exhaustion and immunogenic cell death.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveGastric cancer (GC), a widely recognized malignant neoplasm, poses significant treatment challenges. It is essential to pursue additional research to uncover novel therapeutic approaches and predictive methodologies. The phenomenon of disulfidptosis, recently identified as a distinct type of programmed cell death, offers intriguing possibilities for therapeutic applications.
methodThis study performed differential analysis, GO analysis, KEGG, GSEA, and other analyses to investigate the relationship between disulfidptosis-related LncRNAs (DRLs) and TCGA GC data. The analysis included 373 gastric cancer samples and 32 normal gastric tissue samples, obtained from [specify data source, e.g., TCGA, GEO, or in-house cohorts]. Samples were rigorously screened based on [criteria, e.g., histopathological confirmation, RNA quality, or clinical completeness], and transcriptomic data were processed using [specific tools or pipelines] to ensure reproducibility. A new, more accurate predictive model was constructed, identifying potential therapeutic targets, signaling pathways, and sensitive drugs.
resultsA refined prognostic signature associated with disulfidptosis in GC was developed through over 200 Lasso regression and MultiCox calculations. It was discovered that AL359182.1 and AC107021.2 could influence GC prognosis by modulating the MYH10/LIGHT JUNCTION or MYH10/REGULATION OF ACTIN CYTOSKELETON pathways. Notably, AL359182.1, newly identified as linked to GC prognosis, emerges as a potential novel therapeutic target. Furthermore, this study enhanced the accuracy of immunotherapy evaluations and screened for potential sensitive drugs.
conclusionLeveraging DRLs and TCGA GC data, this research identified highly precise prognostic signatures consisting of four LncRNAs: PINK1-AS, AC107021.2, AL359182.1, and AC009486.1. The discovery of two new signaling pathways could impact the prognosis of GC. AL359182.1 is proposed as a novel potential therapeutic target. The identified signature also effectively predicts the immunogenicity of GC and facilitates the screening of sensitive drugs. Further experimental validation is suggested to strengthen these conclusions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.